Retatrutide
Also known as LY3437943 · triple agonist · GLP-1/GIP/glucagon
New
Reconstitution & dosing guide
5 mg · 10 mg · 15 mg · 20 mg · 30 mg · 50 mg vial sizes — research phases, recon steps, and a live unit calculator.
Available sizes & price
Catalog only10mg x 10 vials
Retatrutide (RT10) · Not in current stock
$55 / vial
15mg x 10 vials
Retatrutide (RT15) · Not in current stock
$80 / vial
20mg x 10 vials
Retatrutide (RT20) · Not in current stock
$90 / vial
30mg x 10 vials
Retatrutide (RT30) · Not in current stock
$125 / vial
5mg x 10 vials
Retatrutide (RT5) · Not in current stock
$35 / vial
50mg x 10 vials
Retatrutide (RT50) · Not in current stock
$200 / vial
Prices per vial · Research use only · Not medical advice.
Investigational triple agonist (GLP-1/GIP/glucagon) with very high weight-loss results in mid-stage trials.
How to picture it
A triple key: GLP-1 + GIP + glucagon receptor activity. Picture a three-channel thermostat for intake and fuel use — appetite quieting and incretin support from the first two paths, plus glucagon-linked energy-expenditure and liver fuel-handling biology from the third. That completeness is why next-generation obesity and metabolic studies pay so much attention: not just an appetite mute button, but multi-pathway metabolic control.
Research focus & benefits
- Triple agonist metabolic and weight research interest
- Appetite, incretin, and energy-expenditure pathway studies
- Next-generation obesity science focus
Benefits describe research interest and pathway rationale — not guaranteed outcomes or medical advice. Research use only.
Overview
Retatrutide is an investigational multi-receptor agonist generating intense interest after Phase 2 data showed large body-weight reductions. It is not an approved consumer peptide; research-market products labeled as retatrutide are unverified and risky.
Mechanism
Simultaneous agonism at GLP-1, GIP, and glucagon receptors — combining appetite suppression with potential energy-expenditure effects via glucagon pathways.
Research uses
- Obesity clinical development
- Metabolic disease trials
- Liver fat research
Research dosing notes
No approved consumer dose. Clinical trial titration only.
Half-life / kinetics
Long-acting; weekly-style clinical regimens under study
Common research routes
Reported considerations
- GI effects similar to incretins
- Heart-rate increases reported in trials
- Unknown long-term profile
Contraindications / cautions
- Not for self-experimentation
- Pregnancy
- Standard incretin cautions
Common research stacks
- Not established outside trials
Legal / access note
Not FDA-approved as of the last major development updates for general use; investigational status. Market research products are unregulated.